...
首页> 外文期刊>Lipids in Health Disease >Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
【24h】

Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil

机译:将EPA和DHA掺入血浆磷脂中以响应不同的omega-3脂肪酸制剂-鱼油与磷虾油的生物利用度比较研究

获取原文
           

摘要

Background Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. Methods In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. Results The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC0-72 h: 80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC0-72 h: 59.78 ± 36.75%*h) and EE (mean AUC0-72 h: 47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. Conclusion Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials.
机译:背景ω-3脂肪酸(FA)的生物利用度取决于其化学形式。磷虾油中磷脂(PL)结合的omega-3 FA具有较高的生物利用度,但尚未比较相同剂量的不同化学形式。方法在一项双盲交叉试验中,我们比较了三种鱼油(再酯化的三酰基甘油酯[rTAG],乙基酯[EE])和磷虾油(主要是PL)衍生的EPA + DHA制剂的摄入量。血浆PL中FA成分的变化被用作生物利用度的替代指标。将十二名健康的年轻男性(平均年龄31岁)随机分配到1680 mg EPA + DHA,分别以rTAG,EE或磷虾油的形式服用。服药前和服用胶囊后2、4、6、8、24、48和72小时分析血浆PL中的FA水平。此外,分析了所应用的补充剂中游离EPA和DHA的比例。结果磷虾油(平均AUC0-72 h:80.03±34.71%* h),其次是鱼油rTAG(平均AUC0-72 h:59.78±36.75%* h)引起了EPA + DHA在血浆PL中的最高掺入。和EE(平均AUC0-72小时:47.53±38.42%* h)。由于高标准偏差值,三种处理之间的DHA和EPA + DHA水平之和没有显着差异。但是,观察到EPA生物利用度差异的趋势(p = 0.057)。统计学上的成对分组比较显示了rTAG和磷虾油之间的趋势(p = 0.086)。补充剂的FA分析表明,磷虾油样品包含的EPA总量为游离EPA的22%,DHA的总量为游离DHA的21%,而两个鱼油样品均不含任何游离FA。结论需要进行更长时间,更大样本量的进一步研究,以证实我们的发现并确定LC n-3 FA的三种常见化学形式(rTAG,EE和磷虾油)之间EPA + DHA生物利用度的差异。磷虾油中出乎意料的游离EPA和DHA含量过高,可能会对磷虾油中EPA + DHA的可用性产生重大影响,应进行更深入的研究,并在以后的试验中予以考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号